Works matching IS 15257304 AND DT 2025 AND VI 26 AND IP 4

Results: 11
    1

    Tepotinib Plus an EGFR Tyrosine Ainase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 4, p. 338, doi. 10.1016/j.cllc.2025.02.013
    By:
    • Xiuning Le;
    • Eisert, Anna;
    • Te-Chun Hsia;
    • Vivek Raut, Nirmal;
    • Azura Ahmad;
    • Siu Hong Chan, Oscar;
    • De Bondt, Charlotte;
    • Farrugia, David;
    • Froesch, Patrizia;
    • González-Cao, Maria;
    • Hendriks, Lizza;
    • Hochmair, Maximillian J.;
    • Mazieres, Julien;
    • O'Sullivan, Hazel;
    • Popat, Sanjay;
    • Samol, Jens;
    • van der Wekken, Anthonie J.;
    • Tsung-Ying Yang;
    • Lye Mun Tho;
    • Himpe, Ulrike
    Publication type:
    Article
    2

    First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 4, p. 331, doi. 10.1016/j.cllc.2025.03.001
    By:
    • Corre, Romain;
    • Decroisette, Chantal;
    • Auliac, Jean-Bernard;
    • Falchero, Lionel;
    • Curcio, Hubert;
    • Amrane, Karim;
    • Perol, Maurice;
    • Hominal, Stéphane;
    • Vieillot, Sabine;
    • Huchot, Eric;
    • Desage, Anne Laure;
    • Bernardi, Marie;
    • Veillon, Remi;
    • Doubre, Hélène;
    • Bota, Suzanna;
    • Legarff, Gwenaelle;
    • Justeau, Grégoire;
    • Bylicki, Oliver;
    • Roa, Magali;
    • Descourt, Renaud
    Publication type:
    Article
    3

    The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 4, p. 324, doi. 10.1016/j.cllc.2025.03.010
    By:
    • Kicken, Mart P.;
    • Heine, Rob Ter;
    • Azarfane, Intissar;
    • de Rouw, Nikki;
    • de Vries, Fenna;
    • Peters, Bas J. M.;
    • Lankheet, Nienke A. G.;
    • Eektimmerman, Frank;
    • Beerden, Tim;
    • Franssen, Eric J. F.;
    • Krens, Lisanne L.;
    • van der Leest, Cor H.;
    • Smit, Arthur A. J.;
    • Polman, Albert J.;
    • Vermeer, Laura C.;
    • van Putten, John W. G.;
    • van den Borne, Ben E. E. M.;
    • van den Heuvel, Michel M.;
    • Deenen, Maarten J.
    Publication type:
    Article
    4

    Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Ad enocarcinorna With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 4, p. 314, doi. 10.1016/j.cllc.2025.02.016
    By:
    • June Hong Ahn;
    • Sun Ha Choi;
    • Sun Hyo Park;
    • Insu Kim;
    • Jin Han Park;
    • Ji Yeon Kim;
    • Tae Hoon Kim;
    • Taehoon Lee;
    • Hyun Kyu Cho;
    • Jong Hwan Jeong;
    • Jung Wook Yang;
    • Ji Eun Park;
    • Tae Hun Kim;
    • Hyun-Kyung Lee;
    • Ho Young Lee;
    • Ho Jin Jung;
    • Jinmi Kim;
    • Jungmin Son;
    • Jung Seop Eom
    Publication type:
    Article
    5
    6
    7

    Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 4, p. 288, doi. 10.1016/j.cllc.2025.01.014
    By:
    • Barrichello, Adriana P. C.;
    • Elkrief, Arielle;
    • Ricciuti, Biagio;
    • Ganta, Teja;
    • Marron, Thomas U.;
    • Xinan Wang;
    • Lotter, William;
    • Lindsay, James;
    • Santo, Valentina;
    • Cortellini, Alessio;
    • Sharma, Bijaya;
    • Felt, Kristen;
    • Pfaff, Kathleen;
    • Lamberti, Giuseppe;
    • Pecci, Federica;
    • Di Federico, Alessandro;
    • Makarem, Maisam;
    • Gandhi, Malini M.;
    • Nguyen, Tom;
    • Haradon, Danielle
    Publication type:
    Article
    8
    9
    10

    The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase H Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 4, p. 267, doi. 10.1016/j.cllc.2025.02.002
    By:
    • Roisman, Laila C.;
    • Mann, Shir;
    • Basel, Afifi;
    • Marei, Ranin;
    • Krayim, Belal;
    • Kornev, Gleb;
    • Asna, Noam;
    • Peled, Nir
    Publication type:
    Article
    11